Imatinib (Glivec, Gleevec; Imkeldi oral solution)

Imatinib at a glance

Imatinib is a targeted cancer medicine that blocks certain abnormal growth signals. Verified brands include Glivec and Gleevec tablets and Imkeldi oral solution. Generic products are also available. The exact product matters because preparation and missed-dose instructions can differ.

Treatment is taken by mouth with a meal and a large glass of water. The dose and duration depend on the condition, relevant test results and your response. Many people take it for a long time, with regular checks for benefit and side effects.

Swelling, nausea, diarrhoea, muscle cramps, rash and tiredness are recognised effects. Blood counts, liver and kidney function need monitoring.

How imatinib works

Cells use proteins called tyrosine kinases to pass on growth signals. Some cancers develop an abnormal kinase or a gene change that keeps a growth signal active. Imatinib blocks several of these targets, including BCR::ABL1, KIT and platelet-derived growth factor receptors, called PDGFR.

BCR::ABL1 is formed when parts of two genes become joined together. It is associated with the Philadelphia chromosome, which you may see described as “Ph-positive” in a report. KIT and PDGFR are different signalling proteins. Which target matters depends on your condition; these are not interchangeable test results.

Imatinib is a tyrosine kinase inhibitor, or TKI. It is not an immune checkpoint treatment or conventional chemotherapy, although it may be prescribed alongside other cancer medicines. Blocking a relevant signal can control abnormal cell growth, but benefit is not guaranteed and resistance can develop. Normal tissues can also be affected, which is why targeted treatment still causes side effects.

How the team decides whether it is suitable

The specialist considers your diagnosis, the exact molecular or chromosome findings, previous treatment, other illnesses and treatment goals. Some results predict sensitivity, while others suggest that imatinib will not work well. A report saying “KIT” or “PDGFR” needs interpretation beyond the name alone. Your team explains which result supports the recommendation.

Ask how treatment goals influence monitoring and duration.

Tell the team about medicine allergies, heart, kidney or liver disease, previous hepatitis B, swelling, bleeding, stomach problems and thyroid surgery. Kidney or liver impairment may require a different dose or closer monitoring. US and European dose-adjustment instructions differ, so the specialist uses the applicable product information rather than a universal dose formula.

Before treatment starts

Baseline checks include blood counts, liver and kidney function, weight and an assessment of fluid retention. Testing for hepatitis B is important because previous infection can reactivate. A positive result does not automatically rule out treatment; a liver or infection specialist may arrange preventive treatment and monitoring. Pregnancy testing is needed when relevant.

The team assesses whether rapid cancer-cell breakdown could cause tumour lysis syndrome. Dehydration and high uric acid should be corrected before treatment, with further preventive measures for people at greater risk.

Heart tests are tailored to your history. In disorders involving high levels of eosinophils, a type of white blood cell, the specialist may arrange an echocardiogram and a troponin blood test before starting. Heart involvement can occasionally worsen when treatment begins; selected patients need steroids and closer supervision. This is not a steroid requirement for everyone taking imatinib.

Bring a complete medicine list, including painkillers, blood thinners, supplements and herbal remedies. Before leaving, understand your dose, meal timing, product-specific preparation and out-of-hours contact plan.

How to take imatinib

Dose, food and schedule

Take each dose with a meal and a large glass of water to reduce stomach irritation. A common adult dose is 400 mg daily, but some people need less or more. Doses of 400 mg or 600 mg are generally taken once daily; 800 mg daily is given as 400 mg twice daily. These are examples, not instructions to change your prescription. For an 800 mg daily dose, the labels specify 400 mg tablets rather than many 100 mg tablets, to limit exposure to iron in the coating.

Children's doses are calculated using body size and their condition. Do not calculate a child's dose from the adult examples. US and European maximum doses differ in some paediatric settings, making the child's written prescription particularly important.

Most schedules are continuous. Contact the team if side effects, cost or supply difficulties interfere with regular treatment. Do not ration tablets or introduce a treatment break yourself.

Tablets and swallowing difficulty

Glivec and Gleevec tablets come in 100 mg and 400 mg strengths. If you cannot swallow the tablets, their product information permits dispersing them in water or apple juice: approximately 50 mL for each 100 mg tablet or 200 mL for each 400 mg tablet. Stir until the tablets have broken down completely and take the entire mixture immediately. The pharmacist should show you the method for your prescription.

Do not crush tablets into powder. Avoid skin contact with broken or crushed medicine. Ask before splitting a scored tablet or adapting another manufacturer's product. Some sources discuss capsules, but capsule opening instructions must come from the exact product leaflet and pharmacist. Do not assume the tablet method works for every capsule or feeding tube.

Imkeldi oral solution

Imkeldi contains 80 mg of imatinib in each mL. It is a supplied oral solution, not the same preparation as a tablet dispersed in water. Have the pharmacist write your dose in both milligrams and millilitres and demonstrate the bottle adapter and oral syringe. Do not use a kitchen teaspoon.

The instructions require disposable gloves when preparing, measuring, taking or giving Imkeldi. Give it slowly into the inside of the cheek while sitting or standing upright, not towards the back of the throat. Follow the instructions for cleaning and fully drying the syringe. Take it with a meal and a large glass of water. The product is for oral use; a feeding-tube method needs specialist confirmation.

Keep it in its original bottle and record the opening date. Discard an opened bottle after thirty days through the pharmacy's recommended disposal process, even if liquid remains.

Missed doses and vomiting

US Gleevec and Imkeldi instructions say to skip a missed dose and take the next scheduled dose at the normal time. The European Glivec leaflet instead says to take it when remembered unless it is nearly time for the next dose. Follow the instructions for your own product; never take two doses together to catch up. Ask the pharmacist if the timing is unclear.

If you vomit after a dose, do not take an extra replacement dose. Take the next at the usual time and seek advice if vomiting continues or fluids will not stay down. An accidental extra dose needs immediate medical advice.

Storage and handling

Keep medicine in its original packaging away from children, following the pack's moisture and temperature instructions. US Gleevec and Imkeldi specify 20–25°C (68–77°F), with limited permitted temperature excursions; check storage for your particular product. Return unused medicine safely rather than using household waste or wastewater.

Monitoring and checking whether treatment is working

The US label recommends a complete blood count weekly during the first month, every two weeks during the second month, and periodically afterwards according to clinical need. Liver function is checked before treatment and usually monthly, or as clinically indicated. Kidney function is assessed before and during treatment, since a decline can occur with long-term use.

Your team reviews weight and swelling. Ask how often to weigh yourself and what change should trigger a call. If you have had your thyroid removed and take levothyroxine, thyroid-stimulating hormone, or TSH, needs closer monitoring because replacement requirements can change. Children need growth monitoring.

The way response is measured depends on the disease. For BCR::ABL1-driven chronic myeloid leukaemia, specialised blood tests measure molecular response, meaning the amount of detectable abnormal gene signal. These differ from routine blood counts. Other treatment settings may rely more on scans, examination and symptoms.

A dose reduction or temporary hold can make treatment safer without automatically meaning it has failed. If response changes, the team considers missed doses, interactions and disease resistance before recommending the next step.

Common side effects and practical management

Swelling and fluid retention

Puffiness around the eyes or swelling in the ankles can develop. Tell the team, especially when it is new or increasing. They may adjust treatment or prescribe medicine to remove extra fluid. Do not start water tablets or sharply restrict fluids yourself.

Rapid weight gain, increasing abdominal swelling, breathlessness or difficulty lying flat can mean fluid is collecting more seriously, including around the lungs or heart. Contact the team urgently; severe breathing difficulty is an emergency.

Nausea, diarrhoea and abdominal discomfort

Taking imatinib with a meal and water is important. Use prescribed anti-sickness or anti-diarrhoea medicines according to your plan. Smaller meals may be easier when appetite is poor.

Contact the team if diarrhoea persists, you cannot drink, you are dizzy or you pass less urine. Agree a fluid plan if you also have swelling, heart disease or kidney problems. Severe abdominal pain, blood in stools or black tar-like stools requires urgent assessment rather than routine diarrhoea treatment.

Muscle cramps, joint pain and tiredness

Muscle cramps and aches can interfere with sleep or activity. Gentle stretching and an activity plan suited to your energy may help. Ask before taking painkillers, magnesium, calcium or other supplements; cramps do not automatically mean a deficiency. Blood tests may identify a treatable change.

Plan rest around important tasks and report fatigue that suddenly worsens. Anaemia, poor intake, sleep disturbance or another illness may contribute. Severe muscle pain or weakness with dark urine needs urgent advice because muscle breakdown has been reported.

Skin, hair and mouth changes

Rash, itching, dry skin or changes in skin colour can occur. Use gentle skin care and recommended moisturisers. Imatinib can increase sensitivity to sunlight, so minimise strong direct sun and use protective clothing and high-factor sunscreen. Report a worsening rash rather than treating it with unfamiliar products.

Hair thinning or altered hair growth may occur. A sore mouth or taste changes can affect eating; gentle oral care and prescribed treatment can help. Painful blisters, peeling, fever with a widespread rash or sores affecting the eyes or genitals are urgent warning signs, not routine dryness.

Low blood counts

Reduced white blood cells increase infection risk, low platelets increase bleeding or bruising, and low red blood cells can cause fatigue or breathlessness. These changes may also reflect the underlying condition, so blood tests and specialist interpretation are important.

Report fever, shivering, unusual bruising, nosebleeds or sudden worsening tiredness. Do not wait for the next blood test if you feel acutely unwell. The team may hold or adjust treatment while counts recover.

Less common but important side effects

Heart, lung and kidney problems

Heart failure or reduced heart-pumping function has been reported, especially in people with other risk factors. New breathlessness, chest discomfort, rapid weight gain or worsening swelling needs assessment. Fluid overload, infection and lung inflammation can produce overlapping symptoms; do not try to distinguish them at home.

Kidney function can decline, including during prolonged treatment. Report markedly reduced urine or worsening swelling, and attend monitoring even when you have no symptoms. Avoid dehydration and have new medicines checked for effects on the kidneys.

Liver injury and hepatitis B reactivation

Imatinib can cause serious liver injury, including during long-term use. Yellow skin or eyes, dark urine, pain under the right ribs or pronounced loss of appetite with feeling unwell needs urgent advice. Liver abnormalities may first appear on routine tests.

A previous hepatitis B infection can become active again, sometimes causing severe liver failure. People with evidence of infection need a specialist plan during treatment and for several months after stopping. Do not stop prescribed antiviral medicine without that team's advice.

Bleeding and gastrointestinal perforation

Bleeding may occur within the digestive tract or a tumour, as well as from low platelets. A stomach blood-vessel problem called gastric antral vascular ectasia can also cause bleeding. Do not assume new blood loss is an expected, harmless side effect.

Vomiting blood, black tar-like stools, major bleeding or faintness with bleeding needs emergency help. Rarely, a hole can form in the stomach or bowel wall. Severe persistent abdominal pain, especially with a swollen abdomen, fever or collapse, needs urgent hospital assessment.

Tumour lysis syndrome and small-vessel injury

Tumour lysis syndrome happens when many abnormal cells break down quickly and release substances into the blood. The resulting chemical changes can harm the kidneys and heart. The team assesses risk and may arrange extra blood tests, fluids or preventive medicines. New marked weakness, vomiting, reduced urine, palpitations, confusion or muscle spasms needs urgent assessment.

Thrombotic microangiopathy is a different condition involving injury and small clots in tiny blood vessels. It can damage blood cells and organs. Unusual bruising together with marked weakness, fever, reduced urine, confusion or neurological symptoms needs urgent help. Treatment must be stopped and specialist tests performed if this condition is suspected. Certain confirmatory findings mean it must not be restarted.

Severe skin reactions and allergy

Severe reactions can include Stevens–Johnson syndrome, toxic epidermal necrolysis and DRESS, a drug reaction that can affect internal organs as well as skin. A widespread painful rash, blistering, peeling, facial swelling, fever or mouth and eye sores needs urgent assessment. Do not take another dose while seeking emergency care for a severe reaction.

Sudden throat or tongue swelling, breathing difficulty or collapse may indicate a serious allergy. Call emergency services immediately.

Other medicines, supplements and vaccinations

Imatinib is affected by medicine-processing enzymes, particularly CYP3A4, and can also alter levels of other medicines. Rifampicin, some epilepsy medicines and St John's wort can lower its exposure; certain antibiotics and antifungals can increase it. Steroids, heart medicines, cholesterol medicines and transplant medicines may also need review. Strong enzyme-inducing medicines and St John’s wort should be avoided unless the specialist has arranged an appropriate alternative plan. Do not change any prescription independently.

Avoid grapefruit and grapefruit juice because they can increase imatinib exposure. Ask before using supplements, including iron, or regular painkillers. Paracetamol needs particular caution at higher doses or with liver problems; the team can advise a suitable dose rather than assuming every non-prescription medicine is safe.

The labels recommend heparin-based anticoagulation instead of warfarin when a blood thinner is needed. If you already use warfarin, obtain a coordinated plan; do not stop it or substitute another blood thinner yourself. Imatinib can also delay clearance of high-dose methotrexate, requiring specialist monitoring when the medicines are combined.

Have vaccines reviewed before administration. Live vaccines may be unsuitable during treatment; the timing afterwards depends on your immune function and other treatments. Non-live vaccines may be possible but can give less protection. Your oncology team should advise the timing.

Everyday life during treatment

A daily routine linked to a meal can help adherence. Keep a current medication list and contact the team early about supply problems or side effects that make you want to miss doses.

Balance activity with rest and adapt work when cramps, swelling or fatigue interfere. Do not drive or operate machinery when dizzy, sleepy or affected by blurred vision. Tell your dentist and other clinicians that you take imatinib before procedures or new prescriptions.

For travel, organise enough medicine, appropriate storage and required blood tests in advance. Carry treatment details and know how to obtain urgent advice away from home. Use routine hand hygiene and avoid close contact with people who are clearly unwell.

Fertility, contraception, pregnancy and breastfeeding

Imatinib can harm an unborn baby. Pregnancy should be planned with the treating specialist, who must balance treatment needs and reproductive goals. Contact the team promptly if pregnancy occurs or is suspected; do not make an unsupervised treatment change.

For someone who could become pregnant, US Gleevec and Imkeldi advice is highly effective contraception during treatment and for fourteen days after stopping. European Glivec specifies at least fifteen days afterwards. Agree a reliable method and exact stopping date; longer precautions required by another treatment still apply.

The product labels do not specify a fixed male contraception interval. Men planning parenthood should discuss their circumstances with the specialist rather than automatically stopping imatinib. Effects on human fertility remain uncertain, so discuss preservation options before treatment if relevant.

Imatinib and its active metabolite pass into breast milk. Do not breastfeed during treatment. US products specify one month after the last dose; European Glivec specifies at least fifteen days. Follow the product-specific plan agreed with the team rather than choosing the shorter interval yourself.

After treatment finishes

Continue follow-up for unresolved blood-count, kidney, liver or fluid-retention problems. Follow hepatitis B monitoring and antiviral advice if applicable, and complete the contraception and breastfeeding precautions.

Some carefully selected people with chronic myeloid leukaemia and a sustained deep molecular response may attempt treatment-free remission under a specialist protocol. This requires frequent sensitive blood tests and clear criteria for restarting. It is not appropriate simply because one result is normal, and it must not be attempted independently.

Muscle or joint pain can appear after stopping imatinib. Report it so that the team can assess and manage it. Return unused medicine safely and do not restart leftover supplies without instructions.

Frequently asked questions